Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors

• Status: Completed
• Trial end date: 2005-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the DLT, MTD and recommended Phase II dose of ixabepilone in Japanese patients with solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb; R-Pharm
• Treatments: Epothilones

Criteria

Inclusion Criteria:

• 20 years or older

• Histologically or cytologically confirmed diagnosis of adenocarcinoma Solid tumors

Exclusion Criteria:

• Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≥2